Jenburkt Pharmaceuticals launches antiviral drug 'Favipiravir' to fight COVID-19

25 Jul 2020 Evaluate

Jenburkt Pharmaceuticals has launched antiviral drug Favipiravir (brand name Favivent) for the treatment of mild to moderate COVID-19 symptoms at a price of Rs 39 per tablet. This is not the first foray into timely, rapid innovation from the Jenburkt stable. This innovation-driven organisation was the first in the world to introduce Nervijen, Metmin-A, Powergesic, Infartin and a few more, across multiple therapeutic areas. The company’s R&D unit, approved by the Ministry of Science & Technology, Government of India, is their gateway to health through innovation.

Jenburkt is the second in India to introduce Favipiravir (brand name Favivent) for the treatment of COVID-19. Favivent is manufactured at a pharmaceutical plant which is compliant with US-FDA (U. S. Food and Drug Administration) and EDQM (The European Directorate for the Quality of Medicines & HealthCare) standards located in the state of Telangana, with the highest safety and manufacturing protocols in place. According to Jenburkt, the medication will be available in the form of 1 strip of 10 tablets.

Jenburkt Pharmaceuticals is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products.

Jenburkt Pharma Share Price

1038.40 5.65 (0.55%)
30-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1830.20
Dr. Reddys Lab 1183.00
Cipla 1549.65
Lupin 2094.65
Zydus Lifesciences 887.70
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...